ArticleCell systems2020
Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.
Open access · hybridAbstract read
In one paragraph
Article in Cell systems, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 113 citations in OpenAlex.
- An optogenetic smart microscopy platform reveals signaling dynamics-dependent control over collective cell migration.Cell systems · 2026Article
- MAPK Inhibitor-Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities.Cancer science · 2026Review
- Design and optimization of a kinase-controlled allosteric switch.Nature methods · 2026Article
- CD44 restricts EGFR mobility to polarize cytoskeletal signalling modules driving bleb-based migration.Nature cell biology · 2026Article
- Patient-specific modeling of G2/M cell cycle dynamics reveals prognostic dynamical regimes driven by copy number alterations.NPJ systems biology and applications · 2026Article
- Integrative multi-omics defines melanoma drug response networks and ARID1A-dependent resistance mechanisms.Molecular systems biology · 2026Article
- Plasticity, signaling, and metabolic rewiring in melanoma persister cells.Communications biology · 2026Review
- Dual RAF inhibition outperforms RAF-MEK combinations for suppressing ERK signaling in KRAS mutant cells.NPJ systems biology and applications · 2026Article
- Predicting targeted- and immunotherapeutic response outcomes in melanoma with single-cell Raman spectroscopy and AI.bioRxiv : the preprint server for biology · 2026Article
- Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma.Communications biology · 2026Article
- Variable thresholds for phosphorylation targets of the ERK signaling pathway.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Reconstructing and comparing signal transduction networks from single-cell protein quantification data.Bioinformatics (Oxford, England) · 2026Article
- Harnessing transcriptomics for discovery of natural products to overcome acquired cancer resistance.Archives of pharmacal research · 2026Review
- Two novel red-FRET ERK bosensors in the 670-720 nm range.Journal of biological engineering · 2025Article
- Quantifying cancer- and drug-induced changes in Shannon information capacity of RTK signaling.Scientific reports · 2025Article
- Unlocking the therapeutic potential of cellular mechanobiology.Science advances · 2025Review
- PyCLM: programming-free, closed-loop microscopy for real-time measurement, segmentation, and optogenetic stimulation.bioRxiv : the preprint server for biology · 2025Article
- MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells.Science signaling · 2025Article
- Systemic Therapy for Melanoma: What Surgeons Need to Know.Surgical oncology clinics of North America · 2025Review
- Deciphering the history of ERK activity from fixed-cell immunofluorescence measurements.Nature communications · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 6 institutions in 1 country.
Luca GerosaLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Christopher ChidleyLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Fabian FröhlichLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Gabriela SanchezLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Sang Kyun LimLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Jeremy MuhlichLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Jia-Yun ChenLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Sreeram VallabhaneniLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Gregory J BakerLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Denis SchapiroLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Mariya I AtanasovaLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Lily A ChylekLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Tujin ShiBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Lian YiBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Carrie D NicoraBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Allison ClaasDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Thomas S C NgCenter for Systems Biology, Massachusetts General Hospital Research Institute, Boston, MA 02114, USA.
Rainer H KohlerCenter for Systems Biology, Massachusetts General Hospital Research Institute, Boston, MA 02114, USA.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital Research Institute, Boston, MA 02114, USA.
Miles A MillerCenter for Systems Biology, Massachusetts General Hospital Research Institute, Boston, MA 02114, USA.
Wei-Jun QianBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
H Steven WileyEnvironmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Peter K SorgerLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: peter_sorger@hms.harvard.edu.
Harvard University · USCenter for Systems Biology · USPacific Northwest National Laboratory · USMassachusetts Institute of Technology · USBroad Institute · USMassachusetts General Hospital · US
Funding
Equipment Supplement Request for a Research Resource for Ultra-sensitive High Throughput ProteomicsP41GM103493 · NIGMS · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI SMITH, RICHARD D · 2012 to 2022
$22.6MSystems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2018 to 2022
$10.8MTrans Network ProjectU54CA210180 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WHITE, FOREST M · 2016 to 2020
$10.2MReverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of CancerU01CA227544 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI QIAN, WEI-JUN, SAURO, HERBERT M. · 2019 to 2023
$3.1MImaging of nanotherapeutic drug actionU01CA206997 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$2.9MSingle Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast CancerR00CA207744 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, MILES A · 2018 to 2020
$747kNCI NIH HHS R00 CA207744NCI NIH HHS U01 CA206997NCI NIH HHS U01 CA227544NCI NIH HHS U54 CA210180NCI NIH HHS U54 CA225088NIGMS NIH HHS P41 GM103493
Abstract
Targeted inhibition of oncogenic pathways can be highly effective in halting the rapid growth of tumors but often leads to the emergence of slowly dividing persister cells, which constitute a reservoir for the selection of drug-resistant clones. In BRAF
Indexed as
Cell Line, TumorDrug Resistance, NeoplasmExtracellular Signal-Regulated MAP KinasesGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemMelanomaMitogen-Activated Protein Kinase KinasesMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafras ProteinsSignal TransductionTumor MicroenvironmentBRAF protein, humanExtracellular Signal-Regulated MAP KinasesMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafras ProteinsBRAF(V600E) melanomacancer persistencekinase inhibitorskinetic modelingMAPK pathwaynon-genetic drug resistancesignaling plasticitysystems pharmacologytargeted therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.